ARTICLE | Company News

Scioderm, Amicus Therapeutics deal

September 7, 2015 7:00 AM UTC

Amicus will acquire Scioderm for $125 million in cash and $104 million in stock up front. The shareholders are eligible for up to $618 million in milestones, including $361 million for clinical and regulatory milestones and $257 million in sales milestones. The deal includes Zorblisa ( SD-101), an undisclosed topical cream to treat epidermolysis bullosa (EB). The company expects data in 1H16 from the Phase III SD-005 trial of the compound and hopes to begin a rolling NDA submission next quarter. Amicus plans to request a Priority Review voucher as part of the submission. If the company obtains and subsequently sells a Priority Review voucher, Scioderm shareholders will receive the lesser of $100 million or 50% of the voucher’s price. Zorblisa has breakthrough therapy designation in the U.S. and Orphan Drug designation in the U.S. and EU for EB. ...